Which treatment is most effective for adults with Achilles tendinopathy? by Winters, M. (Marinus) et al.
Which treatment is most effective for adults with Achilles tendinopathy? A protocol for a living 
systematic review including network meta-analysis 
Marinus Winters1 
Arco C. van der Vlist2 
Adam Weir2,3,4 
Clare L. Ardern5,6 
Nicky J. Welton7 
Deborah M. Caldwell7 
Jan A.N. Verhaar2 
Robert-Jan de Vos2 
 
1. Research Unit for General Practice in Aalborg, Department of Clinical Medicine, Aalborg 
University, Aalborg, Denmark 
2. Department of Orthopaedics and Sports Medicine, Erasmus MC University Medical Center, 
Rotterdam, the Netherlands 
3. Sports Groin Pain Centre, Aspetar Orthopaedic and Sports Medicine Hospital, Doha, Qatar  
4. Sports Medicine and Exercise Clinic Haarlem (SBK). Haarlem, The Netherlands 
5. Division of Physiotherapy, Linköping University, Linköping, Sweden 
6. Division of Physiotherapy, Karolinska Institute, Stockholm, Sweden 
7. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK 
 
Corresponding author: 
Dr. Marinus Winters 
marinuswinters@hotmail.com  
 
  
2 
 
Abstract 
Introduction Achilles tendinopathy is a condition that affects both active and sedentary individuals. It 
is characterized by localized pain in relation to tendon-loading activities. As chronic Achilles 
tendinopathy results in substantial disease burden, it is vital to treat it effectively. There are many 
different conservative and surgical treatments available, but the comparative effectiveness of these 
treatments has never been evaluated.  
Methods and analysis The primary outcome measure of this living systematic review with network 
meta-analysis is the Victorian Institute of Sports Assessment-Achilles (VISA-A) score. The secondary 
outcome measures are return-to-sport (yes/no) at 6–12 weeks, 13–52 weeks and >52 weeks. 
Completed published and unpublished randomized controlled trials with full-text reports are eligible for 
inclusion. We will search Embase, MEDLINE Ovid, Cochrane Central Register of Controlled Trials 
(CENTRAL), Web of Science, and CINAHL, SPORTDiscus and AMED OpenGrey, WorldCat, Google 
Scholar, the WHO trial registry and Clinicaltrials.gov register for potentially eligible trials. Two 
researchers will appraise trial eligibility and perform data extraction. The risk of bias will be assessed 
using the Cochrane Risk of Bias Tool V2. Bayesian network meta-analyses will be constructed for 
VISA-A score and return-to-sport. Consistency between direct and indirect comparisons will be 
assessed. We will explore between study variability, and perform a threshold analysis for the credibility 
of the network meta-analyses’ conclusions.  
Ethics and dissemination No ethical approval is required. The study commenced on 1st November 
2018, and its expected completion date is 15 August 2019. Upon completion, we will seek publication 
in an international peer-reviewed journal and publish translational articles to disseminate the work to 
clinicians. 
Prospero registration number CRD42018086467  
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Introduction 
Achilles tendinopathy is common in active and sedentary individuals.1,2 The incidence in general 
medical practice is 2-3 per 1,000 patients.3 It is most frequent in specific populations; more than half of 
runners will suffer Achilles tendinopathy and hampers return to health-promoting activities.4,5 The 
incidence of Achilles tendinopathy is expected to increase due to intensive campaigns to promote 
physical activity as an intervention for sedentary individuals. Recent qualitative studies report a 
decreased quality of life with impact on the identity, social well-being, living with the condition, 
frustration, and lifestyle adaptations.6,7 The reported reduced work ability due to lower-limb 
tendinopathy is 36% and the associated decreased work productivity is up to 58%.8 The impact 
increases even more when Achilles tendinopathy becomes chronic. This is reflected in the long 
symptom duration. Approximately 60% of patients with chronic Achilles tendinopathy have persistent 
symptoms 5 years after initiating conservative treatment.9  
The clinical diagnosis of Achilles tendinopathy is established in presence of localized Achilles tendon 
pain in relation to tendon-loading activities.10 Different types of Achilles tendinopathy are considered, 
based on location and duration of the disease.10,11 Achilles tendinopathy localized in the midportion – 
2-7 cm proximal from its insertion on the calcaneus – is a different condition compared to Achilles 
tendinopathy localized at the distal bony insertion. Additionally, new-onset reactive Achilles 
tendinopathy is considered to have a different underlying pathology compared to chronic or recurrent 
Achilles tendinopathy. These different entities influence prognosis and treatment options and, 
therefore, they are categorized into 4 groups (Figure 1).12,13 Ultrasound is the most suitable method to 
detect changes in Achilles tendinopathy, as it is widely accessible, user-friendly and has low costs.14 
On ultrasound, tendinopathy can be characterised by tendon thickening, decreased tendon structure 
and/or increased Doppler flow. While additional diagnostics can be used to verify the diagnosis of 
Achilles tendinopathy, the associations between diagnostic abnormalities and patient-reported pain is 
weak.15-18 Therefore, the presence of clinical signs remains the cornerstone for establishing the 
diagnosis.19 
 
Figure 1. Achilles Tendinopathy categorized into 4 different entities  
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Treatment of tendinopathies is challenging for both healthcare providers and patients. Treatments can 
be broadly classified into the following categories: exercise-based therapies, passive modalities, 
medications, injection-based therapies and surgery. The large number of treatment options is 
represented in the number of available systematic reviews. In 2018, at least 9 separate systematic 
reviews on the effects of treatments for Achilles tendinopathy were published.20-28 We also identified a 
number of ongoing systematic reviews into the effectiveness of (groups of) treatments for Achilles 
tendinopathy. While all these reviews focus on different treatment options, the comparative 
effectiveness of all available treatments has never been examined. Being faced with so many 
potentially effective treatments, it is challenging to take an informed shared-decision in clinical practice 
about how to treat the condition.  
Conventional systematic reviews provide head to head comparisons, e.g. exercise therapy versus an 
injection therapy, and injection therapy versus a passive modality. In this approach multiple treatments 
cannot be compared simultaneously, leaving the clinician and patients with incomplete, interpretations 
about the comparative effectiveness of all available treatments.29 Network meta-analysis (NMA) 
provides the opportunity to combine evidence from head to head comparisons with indirect treatment 
comparisons in a single analysis, while maintaining the randomized nature of the evidence. As long as 
the network of treatment comparisons is connected, NMA allows all treatments to be compared, even 
if they have not been investigated head to head in a randomized controlled trial.30-32 Treatments can 
be ranked from “most likely to be effective” to “least likely to be effective” for a given outcome. This 
provides useful information for the shared-decision making process in clinical practice. NMA assumes 
that the included studies do not differ in important factors that interact with treatment effect. 
Systematic reviews are soon out of date, particularly in an ever-evolving field like Achilles 
tendinopathy.33 Living systematic reviews are regularly updated and have the potential to provide a 
comprehensive and up-to-date overview of the comparative effectiveness of all available treatments 
for Achilles tendinopathy.34,35 
The aim of this living systematic review with network meta-analysis is to evaluate the comparative 
effectiveness of all available treatments for adults with any subtype of Achilles tendinopathy, providing 
a comprehensive and consistently updated overview of evidence-based treatments. 
 
Review questions 
1. Which treatments are most likely to be effective for adults with Achilles tendinopathy on the 
VISA-A score, and return to sport activities? 
2. Which treatment classes are most likely to be effective for adults with Achilles tendinopathy on 
the VISA-A score, and return to sport activities? 
3. Which treatment is most likely to lead to (highest levels of) patient satisfaction? 
4. Which treatment class is most likely to lead to patient satisfaction? 
 
Outcome measures 
Primary outcome measure: 
• Victorian Institute of Sports Assessment-Achilles (VISA-A) score. This is an 8-item patient-
reported outcome measure, specifically designed and validated for patients with Achilles 
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tendinopathy.36 The score ranges from 0 – 100, with 0 points indicating worst symptoms 
imaginable, and 100 points indicating no symptoms. 
  
Secondary outcome measures:  
• Return-to-sport (yes/no)  
• Patient satisfaction 
 
Keywords 
Tendon, tendinitis, tendinosis, Haglund deformity, exercise therapy, injection, surgery  
 
Inclusion criteria 
Type of studies 
Published or unpublished randomized controlled trials (RCTs), including randomisation through 
minimisation, or clustering, for which a full report or full protocol of a completed trial is available, are 
eligible for inclusion. RCTs that randomise on the tendon level are only included when study authors 
can provide data that allow re-analysis on the patient level, or when study authors provide such 
results. This will be done by including patients with unilateral pain only. Otherwise, these RCTs will be 
excluded. This is to ensure the NMA provides outcomes relevant at the patient level. Within 
participant-controlled designs (i.e. cross-over studies, or studies using the contralateral Achilles for the 
control arm) will be excluded. Studies having 1 or more treatment arms with ≤10 participants will also 
be excluded. 
 
Type of population 
All patients with a clinical diagnosis of Achilles tendinopathy are included. We will include trials when 
the authors mention that a clinical diagnosis has been made. We will study populations with midportion 
and insertional Achilles tendinopathy, and populations with individuals having a combination of 
midportion and insertional tendinopathy (if such trials exist in the latter case). If the location of Achilles 
tendinopathy is not clear from the report, authors will be contacted. If the type of tendinopathy is still 
unknown, we will exclude the trial from further analyses. The diagnostic criteria used in the original 
trials will be followed. Only trials investigating an adult population with Achilles tendinopathy (age ≥18 
years) will be included to prevent including patients with extra-articular osteochondrosis (Sever’s 
disease).37 Trials including athletes and/or inactive patients will be eligible. Trials evaluating the effect 
of treatment options in full-thickness ruptures of the Achilles tendon will be excluded. 
 
Type of treatments and control treatments 
Any treatment, control treatment, placebo, wait-and-see, or no treatment group studied in a RCT is 
eligible for inclusion. Examples of treatment classes are exercise-based therapies, passive modalities, 
medications, injection-based therapies and surgery. Trials with co-interventions (for example; exercise 
therapy + pain medication) will be eligible, provided that these were applied to all participants in the 
treatment arm. 
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Type of outcomes 
Trials assessing the following outcomes will be included: 
• VISA-A 
• Return to Sport (Yes/No) 
• Patient satisfaction 
 
Methods 
Protocol registration  
The protocol for this living systematic review with network meta-analysis has been registered on 
PROSPERO [CRD42018086467]. This protocol is written based on, and along the lines of, a recently 
published protocol for a living systematic review with network meta-analysis for patients with 
patellofemoral pain.38 We followed the PRISMA-P and PRISMA extension for network meta-analysis 
for reporting systematic review protocols and network meta-analysis.39-41 
 
Patient involvement & prioritising outcomes 
We performed a pilot round of focus interviews with consecutive patients suffering from chronic 
midportion Achilles tendinopathy (n=9) who were participating in an ongoing trial (ClinicalTrials.gov 
Identifier: NCT02996409). We asked which complaints were most disabling and important to patients 
and gained knowledge and experience about how to question patients regarding their Achilles tendon 
pain.  
 
The most frequently mentioned symptoms were restriction in sports participation (n=6), pain during 
daily activities (n=6), stiffness (n=4) and pain due to pressure (e.g. shoes; n=4). After obtaining this 
information and summarizing the results, we sent a digital questionnaire in collaboration with the Dutch 
Patient Federation. We asked 97 patients’ subtype of Achilles tendinopathy and their main treatment 
goal (open question). Twenty-three percent of the patients were <40 years of age, 19% was 40-49 
years, 34% was 50-59 years, 24% was 60-69 years, and <1% was 70 years or older. Forty-nine 
percent was male and 79% participated in regular sports activities. Based on a pain map, 56% 
reported insertional Achilles tendinopathy, 20% midportion Achilles tendinopathy and 24% had a 
combined insertional and midportion Achilles tendinopathy. Forty-four percent of patients discussed 
their treatment aims with their treating physician. 
 
Eighty-five patients (88%) reported their treatment goal(s). The most frequently reported treatment 
goals were 1) participating in sports without mentioning pain status (36%); 2) pain free participation in 
sports (27%); 3) pain free participation in activities of daily living (22%); 4) pain without specification 
(20%) and 5) regaining normal function in activities of daily living without mentioning pain status (9%).  
 
Based on these results, we defined our primary and secondary outcome measures. The VISA-A 
questionnaire quantifies both pain, pain during functioning in activities of daily living and pain during 
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sports, including participation in sports. All these topics are important to patients and therefore we 
decided to define the VISA-A questionnaire as our primary outcome measure.  
 
Search strategy 
One investigator (ACV) and a medical librarian developed a sensitive search strategy for each of the 
data sources. We used a modified version of the Cochrane sensitive search strategy for RCTs.42 The 
strategy includes indexed and free text terms, where applicable (supplementary file, Appendix I). We 
did not impose any restrictions (e.g. language) on our search. 
One investigator (ACV) will search conventional databases, grey literature databases and trial 
registers from their date of inception.  
 
Conventional databases 
Conventional electronic databases Embase, MEDLINE Ovid, Cochrane Central Register of Controlled 
Trials (CENTRAL), Web of Science, and CINAHL, SPORTDiscus and AMED (the latter three via 
Ebsco) will be searched for relevant reports. 
 
Grey literature and ongoing trials 
Databases 
OpenGrey.eu, WorldCat.org and Google Scholar will be searched for unpublished trials. 
 
Trial registers 
We will search the WHO International Clinical Trials Registry Platform (http://apps.who.int/trialsearch/) 
and Clinical Trials.gov, for unpublished or ongoing trials. 
 
Hand searching 
We will screen reference lists of all the trial reports included in our systematic review.  
 
Study selection 
After duplicate removal by one of the investigators, two researchers (ACV, RJV) will screen titles and 
abstracts independently. They will seek consensus in case of initial disagreement. If consensus cannot 
be reached, the report will be included for full text evaluation.  
The two investigators will independently apply inclusion and exclusion criteria to the full text reports. In 
case of disagreement, consensus will be sought. If disagreement persists a third author (AW) will take 
the decision. Reasons for full text exclusion will be documented. 
All selected studies will be uploaded to the Covidence platform (Melbourne, Australia), a not-for-profit 
management system aiming to improve the production and use of systematic reviews for health and 
wellbeing. This software facilitates for independent data selection, extraction and risk of bias 
assessment. 
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Data extraction 
Data will be independently extracted by two random pairs of researchers (ACV, AW, CLA, RJV) using 
standardised extraction forms adopted from the Cochrane Collaboration.43 Disagreements will be 
resolved by seeking consensus, and by a fifth reviewer (MW) in case of persistent disagreement. The 
following data will be extracted: 
• Publication and trial details: e.g. authors, year of publication, funding source, aim study, and 
design 
• Population: e.g. number of included patients, population characteristics for age, sex, setting where 
population was recruited, baseline scores for outcome measures (mean, standard deviations 
(SDs), standard errors extracted for continuous outcomes, and number and percentage for 
categorical outcomes) 
• Eligibility criteria and diagnostic criteria used for Achilles tendinopathy 
• Treatments: e.g. number randomized to group, detailed description of application, dose, intensity, 
frequency, adherence. We used items from the Template for Intervention Description and 
Replication (TIDierR) checklist to assure comprehensive data extraction in this section of the 
extraction form.44  
• Outcomes: e.g. time points measured and reported upon, outcome definition, person measuring, 
scales (upper and lower limits), imputation of missing data.  
• Data and analysis: comparisons, outcomes, subgroups, time points, results (central estimates and 
measures of dispersion; e.g. mean for both groups, mean difference, SDs/95% confidence 
intervals/standard errors), number of missing patients, statistical methods used and 
appropriateness of these methods. 
• Other information: study authors’ key conclusions 
 
Risk of bias assessment 
We will use the Cochrane Risk of Bias Tool v2 to assess the risk of bias for each outcome per study, 
and for outcomes across a (direct) comparison. We will assess risk of bias on the basis of “assignment 
to intervention” (following the “intention-to-treat” principle). The Cochrane Risk of Bias tool has a fixed 
set of domains to use for the risk of bias appraisal, i.e. ‘bias arising from the randomization process’, 
‘bias due to deviations from intended interventions’, ‘bias due to missing outcome data’, ‘bias in 
measurement of the outcome’, ‘bias in selection of the reported result’, and overall risk of bias 
judgement for each outcome.45,46  
 
Sets of reviewer pairs (ACV + one of the following authors: MW, CLA, AW or RJV) will independently 
assess risk of bias for each outcome within the study, for each follow-up. Each major domain of bias 
will be appraised for each outcome. The tool’s signalling questions and criteria will be followed to 
inform a domain-based appraisal of the risk of bias.45,46 The risk of distortion of the outcome estimate 
will be appraised as at ‘low’, ‘some’ or ‘high’ risk of bias, according to Risk of Bias Tool v2 guideline. 
Judgements will be made regarding the direction of distortion ‘favours experimental’, ‘favours 
comparator’, ‘towards null’, ‘away from null’, or ‘unpredictable’. Each outcome within a study will 
9 
 
receive an overall risk of bias judgement based on the individual domains; ‘low’, ‘some’ or ‘high’ risk of 
bias.45,46 Consensus will be sought through discussions in case of disagreements between reviewers. 
A third reviewer (not part of the reviewer pair; i.e. MW, AW, CLA or RJV) will make the decision if 
disagreement persists.  
 
Data synthesis and statistical methods 
We plan a network meta-analysis (NMA) to assess which treatments for Achilles tendinopathy are 
most efficacious. Networks of treatment comparisons will be constructed for midportion, insertional 
and mixed Achilles tendinopathy separately, and for the primary and secondary outcome separately. 
Three authors (ACV, MW, RV) will appraise the clinical homogeneity before any analysis is 
commenced, by tabulating study and population characteristics and inspecting them for differences in 
potential effect modifiers. This is to assess the assumption of exchangeability required for NMA. In 
addition, treatments will be assigned to a class, e.g. exercise therapy, medical therapy or surgery. 
 
Bayesian network meta-analysis 
Networks will be modelled following the Bayesian approach, using Markov chain Monte Carlo 
simulations in WinBUGS (v1.4, Medical Research Council, United Kingdom, and Imperial College of 
Science, Technology and Medicine, University of Cambridge, United Kingdom). We will estimate 
direct, pair-wise comparisons first. For treatments that are connected in a network of comparisons, we 
will estimate relative treatment effects using network meta-analysis. We will also group treatments into 
treatment classes, and fit a hierarchical network meta-analysis, to allow both treatment and class 
effects to be estimated.47,48 Continuous outcomes will be presented as mean difference (MD), with 
their 95% credible intervals when outcomes are measured with the same instrument. We will present 
standardised MDs if different continuous measures are used to evaluate the same construct. We will 
make attempts to model a time-course function for the continuous outcome VISA-A if sufficient data for 
this to be possible. We will group outcome follow-ups for return to sport, and for VISA-A if a time 
function is not feasible, based on the available data, seeking the following approximate timeframes; 6-
12 weeks, 13 – 52 weeks and >52 weeks. If there are multiple time points available for an outcome, 
and these are equally close to the time point to be synthesised across trials, the last follow-up in this 
timeframe will be used. For >52 weeks, a slightly different approach will be followed, where multiple 
time points will be synthesized following available follow-up data.  
We will use surface under the cumulative ranking curves (SUCRAs) and probability ranks to estimate 
the likelihood of individual treatments being superior than the other treatments. 
 
Assessing statistical heterogeneity and exploring it with individual participant data 
Fixed and random effects models will be fitted and we will compare model fit using the deviance 
information criterion and posterior mean residual deviance. Lower deviances depict a better model fit. 
We will assess statistical heterogeneity by inspecting the between trial standard deviation, and 
comparing fit of the fixed and random effect models. Depending on resources and data availability, 
individual participant data from a previous randomized controlled trial by our group, will be used 
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together with trial level data to explore statistical heterogeneity.49 Otherwise, only study level data will 
be used. The following factors are considered for exploration when sufficient data are available (>10 
studies/events per variable), in the following order: symptom duration, active or sedentary population, 
sex and publication status (published/unpublished).50-52 
 
Exploring inconsistency in the network 
We will test the consistency assumption for each network. Results from a model that assumes 
consistency will be compared with a model that relaxes the consistency assumption, to assess 
whether there is evidence of inconsistency. To this end, we will examine model fit by comparing the 
models’ residual deviance and deviance information criterion. If evidence of inconsistency is identified, 
we will use the node-split method to identify where in the network the inconsistency is.53 We will use a 
Bonferroni correction for interpreting multiple P-values. 
 
Assessing small study bias 
We will use comparison-adjusted funnel plots to examine small study bias, if possible. In this 
examination, we assume that small study bias is consistent across comparisons, and experimental 
treatments are more likely to be favoured in small studies compared to control treatments/groups. We 
will evaluate the funnel plot’s distribution, where missing small studies are expected favouring the 
control treatment in the presence of small study bias. We will generate funnel plots for each outcome, 
but only when 10 studies are available.54 Conventional funnel plots for pairwise comparisons will be 
constructed when comparison-adjusted funnel plots cannot be constructed.55  
 
Threshold analysis for credibility of the NMA conclusions 
Risk of bias in the pair-wise estimates has the potential to distort the reliability of the network’s 
estimate, and can affect the credibility of the NMA’s conclusion. We will use a threshold analysis to 
investigate how biased the estimate for each treatment comparisons would have to be before the a 
recommendation based on the posterior mean treatment effect for VISA-A would change.56,57 We will 
perform a threshold analysis where the variance around the bias estimate is assumed to be 0. We will 
assume bias for both measures to over or underestimate treatment effects by maximally 20%, 
following empirical estimations of bias in meta-epidemiological studies.58-60  
 
Potential limitations of the work 
NMA enables comparison of multiple interventions simultaneously and has the potential to provide a 
coherent recommendation for clinical decision-making. Yet, the ability to compare multiple 
interventions in an NMA depends on the availability of the comparisons investigated, and studies 
meeting the assumption of exchangeability. ‘Exchangeable’ means that patients randomized to an 
intervention in one study should have had the ability to be randomized to (other) interventions in 
another study. Coherent recommendations can only be made when the network is connected; it is 
impossible to compare interventions when they are not connected. The strength of the NMA evidence 
depends on the risk of bias in study outcomes across the field of Achilles tendinopathy. NMA assumes 
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that evidence from direct head-to-head studies is consistent with evidence obtained indirectly via the 
network of comparisons. Therefore, we will check the consistency assumption when direct and indirect 
evidence are both available. 
We acknowledge that there are also limitations to the living nature of the proposed research. Living 
systematic reviews are labour intensive and require regular updates. The chance of type 1 errors, i.e. 
incorrectly concluding there is a significant effect in the meta-analysis, increases with the rising 
number of updates. 
 
Administration, dissemination and updating the living systematic review 
This living systematic review will be administered at the Department of Orthopaedics and Sports 
Medicine, Erasmus MC University Medical Center, Rotterdam, the Netherlands. We plan to update the 
network meta-analysis for at least 5 years. The study started at 1 November 2018 and we expect the 
completion date for the first version is 15 August 2019. We plan to update the search and review 
process every 12 months, if needed. We will update the analysis when new data are available. In this 
case, we will present the new findings at the website (www.sportzorg.nl) of the Dutch Sports Medicine 
Association (VSG). Here, we will also provide a plain-language summary for patients and clinicians 
dealing with Achilles tendinopathy. We will seek re-publication in an international peer-reviewed 
journal if there is a change in the conclusions. We will also seek to present the results at national and 
international conferences. We will submit the full text report for “open access” publication in an 
international peer-reviewed journal.  
 
Perspectives 
Systematic reviews on the treatment of Achilles tendinopathy should inform decisions in clinical 
practice. Traditional systematic reviews with pair-wise meta-analysis do not adequately inform these 
decisions when multiple treatments exist. Network meta-analysis is the only design to compare the 
effectiveness of all available treatments for a condition. Although a multitude of systematic reviews on 
the treatment of Achilles tendinopathy are available, patients and clinicians are still in need of 
evidence informing clinical decision-making. Network meta-analysis enables ranking treatments 
according to their probability of being the most effective treatment. In this way, the research directly 
informs the clinician and patient when making a shared decision about how to treat Achilles 
tendinopathy. The ‘living’ nature of this study ensures that clinical decisions are based on the most up-
to-date Level 1 evidence.  
 
Ethics and dissemination 
No ethical approval is required. The study commenced on 1 November 2018, and its expected 
completion date is 15 August 2019. We will seek publication of the work in an international peer-
reviewed journal, as well as translational articles to disseminate the work to clinicians. 
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Appendix I: Search Strategy 
 
Embase.com  
('achilles tendinitis'/exp OR ((tendinitis/de OR pathology/de) AND 'achilles tendon'/de) OR (((achilles 
OR calcaneal) AND (tendinitis* OR tendinopath* OR tendinosis* OR tendonitis* OR tendon-patholog* 
OR pain* OR injur*)) OR achillodyn*):ab,ti) AND ('crossover procedure':de OR 'double-blind 
procedure':de OR 'randomized controlled trial':de OR  'single-blind procedure':de OR (random* OR  
factorial* OR crossover* OR cross NEXT/1 over* OR placebo* OR doubl* NEAR/1 blind* OR singl* 
NEAR/1 blind* OR assign* OR allocat* OR volunteer*):de,ab,ti) 
 
Medline Ovid   
(((Tendinopathy/ OR Pathology/) AND "achilles tendon"/) OR "achilles tendon"/pa OR (((achilles OR 
calcaneal) AND (tendinitis* OR tendinopath* OR tendinosis* OR tendonitis* OR tendon-patholog* OR 
pain* OR injur*)) OR achillodyn*).ab,ti.) AND (Exp Controlled clinical trial/ OR "Double-Blind Method"/ 
OR "Single-Blind Method"/ OR "Random Allocation"/ OR (random* OR factorial* OR crossover* OR 
cross over* OR placebo* OR ((doubl* OR singl*) ADJ blind*) OR assign* OR allocat* OR volunteer* 
OR trial OR groups).ab,ti.) NOT (Animals/ NOT Humans/) 
 
CINAHL EBSCOhost   
(((MH Tendinopathy OR MH Pathology) AND MH "achilles tendon") OR TI (((achilles OR calcaneal) 
AND (tendinitis* OR tendinopath* OR tendinosis* OR tendonitis* OR tendon-patholog* OR pain* OR 
injur*)) OR achillodyn*) OR AB (((achilles OR calcaneal) AND (tendinitis* OR tendinopath* OR 
tendinosis* OR tendonitis* OR tendon-patholog* OR pain* OR injur*)) OR achillodyn*)) AND (MH 
Clinical trials OR MH Randomized Controlled Trials OR MH  Double-Blind Studies  OR MH  Single-
Blind Studies OR MH  Triple-Blind Studies  OR MH Random Assignment OR TI (random* OR 
factorial* OR crossover* OR cross over* OR placebo* OR ((doubl* OR singl*) N1 blind*) OR assign* 
OR allocat* OR volunteer* OR trial OR groups) OR AB (random* OR factorial* OR crossover* OR 
cross over* OR placebo* OR ((doubl* OR singl*) N1 blind*) OR assign* OR allocat* OR volunteer* OR 
trial OR groups)) NOT (MH Animals+ NOT MH Humans+) 
 
SportDiscuss EBSCOhost   
(((MH TENDINITIS OR MH TENDINOSIS  OR MH Pathology) AND MH "achilles tendon") OR TI 
(((achilles OR calcaneal) AND (tendinitis* OR tendinopath* OR tendinosis* OR tendonitis* OR tendon-
patholog* OR pain* OR injur*)) OR achillodyn*) OR AB (((achilles OR calcaneal) AND (tendinitis* OR 
tendinopath* OR tendinosis* OR tendonitis* OR tendon-patholog* OR pain* OR injur*)) OR 
achillodyn*)) AND (TI (random* OR factorial* OR crossover* OR cross over* OR placebo* OR ((doubl* 
OR singl*) N1 blind*) OR assign* OR allocat* OR volunteer* OR trial OR groups) OR AB (random* OR 
factorial* OR crossover* OR cross over* OR placebo* OR ((doubl* OR singl*) N1 blind*) OR assign* 
OR allocat* OR volunteer* OR trial OR groups))  
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AMED EBSCOhost   
(((MH Tendinopathy OR MH Pathology) AND MH "achilles tendon") OR TI (((achilles OR calcaneal) 
AND (tendinitis* OR tendinopath* OR tendinosis* OR tendonitis* OR tendon-patholog* OR pain* OR 
injur*)) OR achillodyn*) OR AB (((achilles OR calcaneal) AND (tendinitis* OR tendinopath* OR 
tendinosis* OR tendonitis* OR tendon-patholog* OR pain* OR injur*)) OR achillodyn*)) AND (MH 
Clinical trials OR MH Randomized Controlled Trials OR TI (random* OR factorial* OR crossover* OR 
cross over* OR placebo* OR ((doubl* OR singl*) N1 blind*) OR assign* OR allocat* OR volunteer* OR 
trial OR groups) OR AB (random* OR factorial* OR crossover* OR cross over* OR placebo* OR 
((doubl* OR singl*) N1 blind*) OR assign* OR allocat* OR volunteer* OR trial OR groups)) NOT (MH 
Animals+ NOT MH Humans+) 
 
Cochrane CENTRAL 
((((achilles OR calcaneal) AND (tendinitis* OR tendinopath* OR tendinosis* OR tendonitis* OR 
tendon-patholog* OR pain* OR injur*)) OR achillodyn*):ab,ti)  
 
Web of science  
TS=(((((achilles OR calcaneal) AND (tendinitis* OR tendinopath* OR tendinosis* OR tendonitis* OR 
tendon-patholog* OR pain* OR injur*)) OR achillodyn*))) AND TS=(random* OR trial* OR rct) 
 
Google scholar  
"achilles|calcaneal tendinitis|tendinopathy|tendinosis|tendonitis" intitle:trial|randomized|randomized|rct 
 
Open grey   
(achilles OR calcaneal) AND (tendinitis OR tendinopathy OR tendinosis OR tendonitis) AND (rct OR 
randomized OR randomized) 
 
Worldcat.org 
kw:(achilles OR calcaneal) AND kw:(tendinitis OR tendinopathy OR tendinosis OR tendonitis)  ti:(rct 
OR randomized OR randomized) 
 
WHO ICTRP  
"achilles tendinitis" OR "Achilles tendinopathy" in title 
 
Clinicaltrials.gov  
"achilles tendinitis" OR "Achilles tendinopathy"  
 
 
 
